Mainz Biomed N.V. (MYNZ) — 6-K Filings

6-K Filings (24)

• Mainz Biomed Amends Articles, Reduces Share Nominal Value — Nov 26, 2025 Risk: low
  Mainz Biomed N.V. filed a Form 6-K on November 26, 2025, reporting a Deed of Amendment executed on November 13, 2025. Key changes include decreasing the nominal
• Mainz Biomed to Sell Up to $10M in Shares — Oct 3, 2025 Risk: medium
  On October 3, 2025, Mainz Biomed N.V. entered into an Equity Distribution Agreement with Maxim Group LLC, acting as Sales Agent. This agreement allows Mainz Bio
• Mainz Biomed Files H1 2025 Financial Report — Sep 26, 2025 Risk: low
  On September 26, 2025, Mainz Biomed N.V. filed a Form 6-K to provide its Management's Discussion and Analysis of Financial Condition and Results of Operations f
• Mainz Biomed Sells Pre-funded Units in Offering — Aug 5, 2025 Risk: medium
  On August 4, 2025, Mainz Biomed N.V. entered into a Securities Purchase Agreement with an institutional investor to sell 2,222,222 pre-funded units. Each unit i
• Mainz Biomed Shareholders Approve All Proposals at Annual Meeting — Jun 5, 2025 Risk: low
  On June 2, 2025, Mainz Biomed N.V. held its Annual General Meeting of Shareholders where all proposed resolutions were approved. The minutes detailing these res
• Mainz Biomed Sells Units and Warrants to Investor — May 21, 2025 Risk: medium
  On May 19, 2025, Mainz Biomed N.V. entered into a Securities Purchase Agreement (SPA) with an institutional investor. The company sold 375,000 ordinary units, e
• Mainz Biomed Schedules Shareholder Meeting, Distributes Proxy Materials — May 2, 2025 Risk: low
  Mainz Biomed N.V. is mailing a power of attorney and voting proxy card to shareholders of record as of May 5, 2025, starting around May 13, 2025. This is in pre
• Mainz Biomed Regains Nasdaq Compliance — Apr 1, 2025 Risk: medium
  On April 1, 2025, Mainz Biomed N.V. announced it has regained compliance with Nasdaq's minimum equity requirement. This means the company is now in compliance w
• Mainz Biomed Discovers mRNA Biomarkers for Pancreatic Cancer — Mar 13, 2025 Risk: medium
  Mainz Biomed N.V. announced on March 13, 2025, a groundbreaking discovery of mRNA biomarkers for blood-based detection of pancreatic cancer. This discovery was
• Mainz Biomed Regains Nasdaq Listing Compliance — Jan 27, 2025 Risk: low
  On January 27, 2025, Mainz Biomed N.V. announced it has regained compliance with all Nasdaq Capital Market listing requirements, specifically addressing the min
• Mainz Biomed Fails Nasdaq Equity Threshold — Jan 14, 2025 Risk: high
  Mainz Biomed N.V. filed a 6-K on January 14, 2025, reporting that on November 27, 2024, they received a determination letter from Nasdaq stating they no longer
• Mainz Biomed Sells Units to Institutional Investor — Dec 16, 2024 Risk: medium
  On December 12, 2024, Mainz Biomed N.V. entered into a securities purchase agreement with an institutional investor to sell 220,165 ordinary units. Each unit in
• Mainz Biomed Prices $8M Follow-On Offering — Dec 13, 2024 Risk: medium
  Mainz Biomed N.V. announced on December 12, 2024, the pricing of a follow-on offering of $8.0 million. The offering was priced at-the-market under Nasdaq rules.
• Mainz Biomed Announces Stock Split — Nov 29, 2024 Risk: low
  Mainz Biomed N.V. announced a stock split on November 29, 2024. This filing incorporates by reference a press release detailing the stock split, which is furnis
• Mainz Biomed Shareholders Approve All Proposals at EGM — Nov 15, 2024 Risk: low
  Mainz Biomed N.V. held an Extraordinary General Meeting of Shareholders on November 13, 2024, where all proposed resolutions were approved by the holders of ord
• Mainz Biomed Partners with Thermo Fisher for Cancer Test Development — Nov 12, 2024 Risk: medium
  On November 6, 2024, Mainz Biomed N.V. entered into a two-year Research Collaboration Agreement with Life Technologies Corporation, a subsidiary of Thermo Fishe
• Mainz Biomed Files 6-K with October Press Release — Oct 21, 2024 Risk: low
  Mainz Biomed N.V. filed a Form 6-K on October 21, 2024, to furnish a press release dated October 21, 2024. This follows their previous disclosure on October 18,
• Mainz Biomed N.V. Files Q2 2024 Financial Update — Oct 18, 2024 Risk: low
  On October 18, 2024, Mainz Biomed N.V. filed a Form 6-K to provide its Management's Discussion and Analysis of Financial Condition and Results of Operations for
• Mainz Biomed Amends Yorkville Pre-Paid Advance Agreement — Oct 9, 2024 Risk: medium
  Mainz Biomed N.V. filed a Form 6-K on October 9, 2024, reporting on a material definitive agreement. This agreement is an amendment to a Pre-Paid Advance Agreem
• Mainz Biomed N.V. Convertible Note Terms Revealed — Oct 3, 2024 Risk: medium
  On September 26, 2023, Mainz Biomed N.V. issued a convertible promissory note to YA II PN, Ltd. The note allows YA II PN, Ltd. to convert the note into ordinary
• Mainz Biomed Shareholders Approve All Proposals at AGM — May 31, 2024 Risk: low
  Mainz Biomed N.V. held its annual general meeting of ordinary shareholders on May 31, 2024, in Amsterdam, The Netherlands. A quorum was present, and all proposa
• Mainz Biomed Schedules Annual Shareholder Meeting for May 31 — Apr 24, 2024 Risk: low
  Mainz Biomed N.V. is holding its annual general meeting of shareholders on May 31, 2024. The company will mail related documents, including the agenda and proxy
• Mainz Biomed Reports on Yorkville Financing Agreement — Apr 19, 2024 Risk: medium
  Mainz Biomed N.V. filed a Form 6-K on April 19, 2024, reporting on a Pre-Paid Advance Agreement (PPA) entered into on June 28, 2023, with YA II PN, Ltd. (Yorkvi
• Mainz Biomed Reports Leadership Changes and Carve-Out Adoption — Feb 23, 2024 Risk: medium
  MAINZ BIOMED N.V. filed a Form 6-K on February 23, 2024, indicating a 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX